Results From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeleta... (Source: Amgen News Release)
Source: Amgen News Release - February 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
PHARMAC expands funding for zoledronic acid
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2018 Category: Drugs & Pharmacology Source Type: news
An international consortium identifies the breast cancer patients who would benefit from a treatment
(Institute for Research in Biomedicine (IRB Barcelona)) This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and it may accelerate the administration of the first preventive treatment of metastasis. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 19, 2017 Category: Biology Source Type: news
Generic vs Brand Bone Drug for Breast Cancer, Skeletal Mets Generic vs Brand Bone Drug for Breast Cancer, Skeletal Mets
Monthly denosumab more effective than zoledronic acid in delaying time to first skeletal-related events but over 2 years cost almost $350K more.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Bone Health Drug Inhibits Mesothelioma Tumor Growth
A drug used to treat bone disease and high blood calcium levels may carry benefits as part of a combination treatment for malignant pleural mesothelioma, a recent study concluded.
Researchers at the University of Alabama at Birmingham Comprehensive Cancer Center conducted a pilot study testing the effects of zoledronic acid — a bisphosphonate, or bone health drug, marketed as Reclast and Zometa — against a small group of patients with unresectable pleural mesothelioma.
The study, published in the June edition of Lung Cancer: Targets and Therapy journal, was a follow-up to preclinical research showing zoledronic acidâ...
Source: Asbestos and Mesothelioma News - July 20, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bone disease treatment keytruda mesothelioma treatments Muhammad Omer Jamil reclast treating malignant pleural mesothelioma University of Alabama at Birmingham Comprehensive Cancer Center Zoledronic acid zometa Source Type: news
New Evidence Points to Benefits of Zoledronic Acid for Advanced...
The bisphosphonate may be an option for mesothelioma patients who are not benefitting from other treatments.(PRWeb July 01, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14478826.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 1, 2017 Category: Pharmaceuticals Source Type: news
Denosumab Shows Benefits in Multiple Myeloma Bone Disease Denosumab Shows Benefits in Multiple Myeloma Bone Disease
In a head-to-head comparison with zoledronic acid, denosumab was noninferior, with prolonged time to a first skeletal event and a reduced risk for renal events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Amgen To Present New Data At 22nd Congress of the European Hematology Association
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma
New Subset Analysis Demonstrates BLINCYTO® (Blinatumomab) More Than Doubled Median Overall Survival Versus Standard of Care Chemotherapy in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage
Oral Presentation of New Data From Head-to-Head Phase 3 Study of XGEVA® (Denosumab) Versus Zoledronic Acid in Time to First On-Study Skeletal-Related Eve...
Source: Amgen News Release - June 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Presents New Data From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017
Analysis Demonstrated XGEVA had a Significantly Lower Rate of Renal Adverse Events Compared to Zoledronic Acid
Data Selected for Best of ASCO® Educational Program
THOUSAND OAKS, Calif., June 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the XGEVA® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. The study met its primary endpoint, demonstrating XGEVA is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p=0.01). The analysis d...
Source: Amgen News Release - June 4, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Mylan Launches Generic Reclast(R) Injection
HERTFORDSHIRE, England and PITTSBURGH, June 2, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Zoledronic Acid Injection, 5 mg/100 mL Single Dose Vial, a generic version of Novartis' Recl... Biopharmaceuticals, Generics, FDA, Product Launch Mylan, Zoledronic Acid, Reclast, Paget's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 2, 2017 Category: Pharmaceuticals Source Type: news
Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio
Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease
XGEVA Study in Patients With Myeloma Bone Disease Also Selected for Best of ASCO®
First Randomized Study to Evaluate the Combination of IMLYGIC® (talimogene laherparepvec), an Oncolytic Viral Immunotherapy, With a Checkpoint Inhibitor to be Presented
THOUSAND OAKS, Calif., May 17, 2017 /PRNewswire/ --Â Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting ...
Source: Amgen News Release - May 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
ACP Updates Guidelines on Treating Low Bone Density, Osteoporosis (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Clinicians should offer alendronate, risedronate, zoledronic acid, or denosumab to women with osteoporosis to reduce the risk for hip and vertebral fractures (strong … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 9, 2017 Category: Primary Care Source Type: news
